Climb Bio, Inc. (CLYM)
| Market Cap | 836.85M +440.5% |
| Revenue (ttm) | n/a |
| Net Income | -57.62M |
| EPS | -0.83 |
| Shares Out | 57.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 840,929 |
| Open | 14.86 |
| Previous Close | 15.06 |
| Day's Range | 14.37 - 15.13 |
| 52-Week Range | 1.54 - 18.33 |
| Beta | 0.08 |
| Analysts | Strong Buy |
| Price Target | 22.57 (+54.91%) |
| Earnings Date | Aug 6, 2026 |
About CLYM
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company’s lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for CLYM stock is "Strong Buy." The 12-month stock price target is $22.57, which is an increase of 54.91% from the latest price.
News
Climb Bio price target raised to $24 from $20 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Climb Bio (CLYM) to $24 from $20 and keeps a Buy rating on the shares. The firm views the company’s competitive positioning…
Climb Bio price target raised to $25 from $17 at Truist
Truist raised the firm’s price target on Climb Bio (CLYM) to $25 from $17 and keeps a Buy rating on the shares.
Climb Bio reports Q2 EPS (18c), consensus (21c)
“2026 is proving to be a defining year for Climb Bio (CLYM), and I am thrilled by the team’s execution,” said Aoife Brennan, President and Chief Executive Officer of Climb…
Climb Bio Earnings release: Q2 2026
Climb Bio released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Climb Bio Quarterly report: Q2 2026
Climb Bio has published its Q2 2026 quarterly earnings report on August 6, 2026.
Climb Bio Slides: Investor presentation
Climb Bio has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
Climb Bio initiated with an Outperform at RBC Capital
RBC Capital analyst Nevin Varghese initiated coverage of Climb Bio (CLYM) with an Outperform rating and $23 price target Climb Bio offers an attractive second half of 2026 catalyst profile,…
Climb Bio price target raised to $20 from $19 at BTIG
BTIG analyst Julian Harrison raised the firm’s price target on Climb Bio (CLYM) to $20 from $19 and keeps a Buy rating on the shares. Budoprutug, an anti-CD19 monoclonal antibody,…
Climb Bio announces initial data from budoprutug study at EHA
Climb Bio (CLYM) announced initial data from the ongoing Phase 1b portion of its Phase 1b/2a study evaluating budoprutug, an anti-CD19 monoclonal antibody, in adults with primary immune thrombocytopen...
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment o...
Climb Bio initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Climb Bio (CLYM) with a Buy rating and $35 price target. Lead asset budoprutug is delivering deep B-cell depletion via a mechanism clinically validated by Amgen’s…
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
Company to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summer
Climb Bio Transcript: Jefferies Global Healthcare Conference 2026
The conference highlighted progress on two antibody programs for renal and autoimmune diseases, with upcoming data at ERA and ASN. Differentiation is driven by advanced technology, global partnerships, and a focus on dosing convenience and efficacy. Regulatory and scientific trends support further development.
Climb Bio registers to sell 11.59M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholder of up to 11.59M shares of common stock. The company is not selling any…
Climb Bio Registration statement: Registration filing
Climb Bio filed a registration statement on May 29, 2026, providing details about a securities offering with the SEC.
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
WELLESLEY HILLS, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, toda...
Climb Bio Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
Climb Bio presented updates on its two lead monoclonal antibody assets targeting serious renal and hematologic diseases, with multiple clinical data readouts expected in 2024. The company highlighted differentiation in safety, dosing, and market positioning, and is well-funded to advance pivotal studies.
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
WELLESLEY HILLS, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, toda...
Climb Bio to Present at Upcoming Investor Conferences
WELLESLEY HILLS, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, toda...
Climb Bio price target raised to $20 from $15 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Climb Bio (CLYM) to $20 from $15 and keeps a Buy rating on the shares post the Q1 report.
Climb Bio price target raised to $17 from $15 at Wedbush
Wedbush raised the firm’s price target on Climb Bio (CLYM) to $17 from $15 and keeps an Outperform rating on the shares. With Climb Bio recently convening its R&D Spotlight…
Climb Bio reports Q1 EPS (20c), consensus (31c)
“During the first quarter, we continued to execute on a focused development strategy aimed at generating clear clinical and translational data across our two programs,” said Aoife Brennan, President a...
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development CLYM116 modeling and initial Phase 1 safety data to be presented at ER...
Climb Bio Earnings release: Q1 2026
Climb Bio released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Climb Bio Quarterly report: Q1 2026
Climb Bio has published its Q1 2026 quarterly earnings report on May 7, 2026.